Published in Med Oncol on September 01, 1998
Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ (2009) 1.57
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer (2010) 1.46
Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. Br J Cancer (2009) 1.09
Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer (2003) 1.04
Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients. Saudi J Gastroenterol (2008) 1.00
Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer (2008) 0.96
Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer (2002) 0.96
Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. Br J Cancer (2006) 0.93
Recombinant erythropoietin in clinical practice. Postgrad Med J (2003) 0.92
Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis. Br J Cancer (2006) 0.82
Recombinant human epoetin beta in the treatment of chemotherapy-related anemia. Ther Clin Risk Manag (2009) 0.77
Recombinant human erythropoietin (rhEPO) in the prevention and treatment of chemotherapy-induced anaemia. Med Oncol (1998) 0.75
Pleiotrophic actions of erythropoietin. Environ Health Prev Med (2003) 0.75
Indications for and complications of transfusion and the management of gynecologic malignancies. Gynecol Oncol (2017) 0.75
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (2003) 8.88
Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis (1994) 4.89
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst (2000) 2.77
The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J Virol (1993) 2.27
Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol (1999) 2.25
Hospital care by hospital-based and clinic-based faculty: a prospective, controlled trial. Arch Intern Med (2001) 2.23
Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax (2004) 2.22
Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol (2005) 2.10
High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res (2001) 2.07
Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol (2005) 2.04
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer (2013) 2.01
Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J Virol (1993) 1.99
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst (2000) 1.99
Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat (1998) 1.97
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol (2002) 1.80
A decade of postlaryngectomy vocal rehabilitation in 318 patients: a single Institution's experience with consistent application of provox indwelling voice prostheses. Arch Otolaryngol Head Neck Surg (2000) 1.79
Detailed structural characterization of succinoglycan, the major exopolysaccharide of Rhizobium meliloti Rm1021. J Bacteriol (1994) 1.76
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol (2000) 1.72
Cytomegalovirus-induced thrombocytopenia and haemolysis in an immunocompetent adult. Br J Haematol (1996) 1.68
Penis conserving treatment for T1 and T2 penile carcinoma: clinical implications of a local recurrence. J Urol (2006) 1.67
Protein kinase C activation by cis-fatty acid in the absence of Ca2+ and phospholipids. J Biol Chem (1986) 1.59
Sequence variants of human papillomavirus type 16 in clinical samples permit verification and extension of epidemiological studies and construction of a phylogenetic tree. J Clin Microbiol (1991) 1.57
Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol (2005) 1.55
EORTC-GCG process quality indicators for ovarian cancer surgery. Eur J Cancer (2008) 1.53
Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res (1992) 1.53
Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J Clin Oncol (2000) 1.51
Discrepancy between laboratory determination and visual estimation of blood loss during normal delivery. Eur J Obstet Gynecol Reprod Biol (1991) 1.47
Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol) (2004) 1.47
Laparoscopically assisted radical vaginal hysterectomy vs. radical abdominal hysterectomy for cervical cancer: a match controlled study. Gynecol Oncol (2004) 1.45
TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus. J Pathol (1999) 1.44
Carcinoma of the fallopian tube. Cancer (2000) 1.43
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer (2002) 1.43
Renal and diaphragmatic endometriosis de novo associated with hormone replacement therapy. J Urol (1995) 1.42
Imaging with pentavalent [99mTc]DMSA in patients with medullary cancer of the thyroid. J Nucl Med (1988) 1.41
Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer (2003) 1.40
Coffee worker's lung. A new example of extrinsic allergic alveolitis. Thorax (1970) 1.40
Unilateral groin and pelvic irradiation for unilaterally node-positive women with vulval carcinoma. Int J Gynecol Cancer (2006) 1.40
Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer? Gynecol Oncol (1993) 1.39
Intra-operative frozen section analysis for suspected early-stage ovarian cancer: 11 years of Gateshead Cancer Centre experience. BJOG (2011) 1.39
Interferon treatment of refractory idiopathic thrombocytopenic purpura (ITP) Eur J Haematol (1994) 1.39
Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study. Int J Gynecol Cancer (2003) 1.38
[Hyoidothyroidopexy as a surgical treatment for obstructive sleep apnoea syndrome]. Ned Tijdschr Geneeskd (2006) 1.38
A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer (1996) 1.37
A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol (1994) 1.37
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol (2010) 1.35
The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol (1995) 1.34
In situ detection of Epstein-Barr virus in gastric and colorectal adenocarcinomas. Am J Surg Pathol (1994) 1.33
Squamous cell carcinoma of the penis. IV. Prognostic factors of survival: analysis of tumor, nodes and metastasis classification system. J Urol (1994) 1.32
Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res (2001) 1.30
Anginex, a designed peptide that inhibits angiogenesis. Biochem J (2001) 1.27
Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet (2004) 1.27
Changes in serum uric acid concentrations during normal pregnancy. Br J Obstet Gynaecol (1984) 1.26
Variation of human papillomavirus type 6 (HPV-6) and HPV-11 genomes sampled throughout the world. J Clin Microbiol (1995) 1.25
Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci (1997) 1.24
Upper urinary tract cancer: location is correlated with prognosis. Eur Urol (2005) 1.24
Alloantigen-reactive Th1 development in IL-12-deficient mice. J Immunol (1998) 1.23
Squamous cell carcinoma of the penis. III. Treatment of regional lymph nodes. J Urol (1993) 1.23
IL-12 antagonism induces T helper 2 responses, yet exacerbates cardiac allograft rejection. Evidence against a dominant protective role for T helper 2 cytokines in alloimmunity. J Immunol (1996) 1.22
Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J Clin Oncol (1999) 1.22
The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol (2004) 1.21
Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg (2010) 1.21
MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer (1998) 1.21
Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg (2004) 1.20
Mannose-binding lectin and rheumatoid arthritis in southern Chinese. Arthritis Rheum (2000) 1.19
Primary structure and mRNA localization of protein F1, a growth-related protein kinase C substrate associated with synaptic plasticity. EMBO J (1987) 1.18
Differential effects of IL-12 receptor blockade with IL-12 p40 homodimer on the induction of CD4+ and CD8+ IFN-gamma-producing cells. J Immunol (1997) 1.17
Human papillomaviruses in 91 oral cancers from Indian betel quid chewers--high prevalence and multiplicity of infections. Int J Cancer (1995) 1.14
High resolution allelotype of microdissected primary nasopharyngeal carcinoma. Cancer Res (2000) 1.14
Isolation of Helicobacter pylori from vomitus in children and its implication in gastro-oral transmission. Am J Gastroenterol (1999) 1.13
Protective effects of curcumin against oxidative damage on skin cells in vitro: its implication for wound healing. J Trauma (2001) 1.13
Cancer in the very elderly Dutch population. Cancer (2000) 1.12
Significance of antibodies to Mycoplasma genitalium in salpingitis. Eur J Clin Microbiol (1987) 1.12
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer (2006) 1.12
Clear cell sarcomas of the kidney registered on International Society of Pediatric Oncology (SIOP) 93-01 and SIOP 2001 protocols: a report of the SIOP Renal Tumour Study Group. Eur J Cancer (2013) 1.12
Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer. Br J Cancer (2000) 1.11
Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol (1992) 1.11
Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease. J Virol (2000) 1.10
Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol (1999) 1.10
Inhibition of the alloantibody response by CD95 ligand. Nat Med (1997) 1.10
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol (2011) 1.09
Evolution of papillomaviruses. Curr Top Microbiol Immunol (1994) 1.09
Infections with Neisseria gonorrhoeae and Chlamydia trachomatis in women with acute salpingitis. Genitourin Med (1985) 1.08
Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol (1992) 1.08
Calcium requirement for axoplasmic transport in mammalian nerve. Nature (1978) 1.08
Can the Hospital Anxiety and Depression (HAD) Scale be used on Chinese elderly in general practice? Fam Pract (1995) 1.08
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol (2006) 1.08
Immunohistochemical detection of P-glycoprotein in human tumor cells with a low degree of drug resistance. Int J Cancer (1989) 1.08
A trans-receptor mechanism for infection of CD4-negative cells by human immunodeficiency virus type 1. Curr Biol (1999) 1.07
Cross-sectional study of semen parameters in a large group of normal Chinese men. Int J Androl (1985) 1.07
Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J Clin Oncol (1999) 1.07
Kinetics of intravenously administered heparin in normal humans. Blood (1982) 1.06
Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group. Semin Oncol (1993) 1.06
The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer (2003) 1.06
Colorectal carcinoma in Hong Kong: epidemiology and genetic mutations. Br J Cancer (1997) 1.05
Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol (1999) 1.04
The Breast Imaging Reporting and Data System (BI-RADS) in the Dutch breast cancer screening programme: its role as an assessment and stratification tool. Eur Radiol (2012) 1.03